[{"address1": "1500 District Avenue", "city": "Burlington", "state": "MA", "zip": "01803", "country": "United States", "phone": "617 600 7373", "website": "https://www.minervaneurosciences.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.", "fullTimeEmployees": 9, "maxAge": 86400, "priceHint": 4, "previousClose": 3.43, "open": 3.33, "dayLow": 3.3091, "dayHigh": 3.4896, "regularMarketPreviousClose": 3.43, "regularMarketOpen": 3.33, "regularMarketDayLow": 3.3091, "regularMarketDayHigh": 3.4896, "beta": 0.116, "forwardPE": -0.9555556, "volume": 15218, "regularMarketVolume": 15218, "averageVolume": 34490, "averageVolume10days": 38730, "averageDailyVolume10Day": 38730, "bid": 2.47, "ask": 4.4, "bidSize": 200, "askSize": 200, "marketCap": 24057330, "fiftyTwoWeekLow": 2.26, "fiftyTwoWeekHigh": 13.49, "fiftyDayAverage": 2.69298, "twoHundredDayAverage": 5.14167, "currency": "USD", "enterpriseValue": 73506080, "floatShares": 5432758, "sharesOutstanding": 6993410, "sharesShort": 27286, "sharesShortPriorMonth": 30475, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.0039, "heldPercentInsiders": 0.22257, "heldPercentInstitutions": 0.30427, "shortRatio": 1.79, "shortPercentOfFloat": 0.0069, "impliedSharesOutstanding": 6993410, "bookValue": -5.232, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -31603746, "trailingEps": -4.43, "forwardEps": -3.6, "lastSplitFactor": "1:8", "lastSplitDate": 1655769600, "enterpriseToEbitda": -3.007, "52WeekChange": -0.4351396, "SandP52WeekChange": 0.26238096, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "NERV", "underlyingSymbol": "NERV", "shortName": "Minerva Neurosciences, Inc", "longName": "Minerva Neurosciences, Inc.", "firstTradeDateEpochUtc": 1404221400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "ceeb0642-b36f-3eda-bb3a-75cdc1b13e8a", "messageBoardId": "finmb_261133065", "gmtOffSetMilliseconds": -14400000, "currentPrice": 3.44, "targetHighPrice": 7.0, "targetLowPrice": 7.0, "targetMeanPrice": 7.0, "targetMedianPrice": 7.0, "recommendationMean": 3.0, "recommendationKey": "hold", "numberOfAnalystOpinions": 1, "totalCash": 34818304, "totalCashPerShare": 4.979, "ebitda": -24447580, "totalDebt": 84267064, "quickRatio": 12.3, "currentRatio": 12.583, "returnOnAssets": -0.29936, "freeCashflow": -18346104, "operatingCashflow": -20763596, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-24"}]